These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30273075)

  • 1. Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice.
    Esposito M; Prignano F; Rongioletti F; Hansel K; Bianchi L; Pescitelli L; Lazzeri L; Ricceri F; Mugheddu C; Bavetta M; Zangrilli A; Bianchi L; Bini V; Stingeni L
    J Dermatolog Treat; 2019 Aug; 30(5):441-445. PubMed ID: 30273075
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic.
    Adenubiova E; Arenberger P; Gkalpakioti P; Arenbergerova M; Jircikova J; Dolezal T; Gkalpakiotis S
    J Dermatolog Treat; 2018 Sep; 29(6):579-582. PubMed ID: 29307245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
    Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis.
    Luan L; Han S; Wang H; Liu X
    Int Immunopharmacol; 2015 Dec; 29(2):278-284. PubMed ID: 26585971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.
    Lombardi G; Perego S; Sansoni V; Diani M; Banfi G; Altomare G
    BMJ Open; 2016 Dec; 6(12):e011941. PubMed ID: 27940624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.
    Yamauchi PS; Bissonnette R; Teixeira HD; Valdecantos WC
    J Am Acad Dermatol; 2016 Sep; 75(3):612-618.e6. PubMed ID: 27061047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris.
    Clemmensen A; Spon M; Skov L; Zachariae C; Gniadecki R
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1037-40. PubMed ID: 21108668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease.
    Navarrete-Dechent C; Majerson D; Torres M; Armijo D; Patel M; Menter A; de la Cruz C
    An Bras Dermatol; 2015; 90(3 Suppl 1):171-4. PubMed ID: 26312707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
    Armesto S; Coto-Segura P; Mayorga J; Illaro A; Santos-Juanes J
    J Dermatolog Treat; 2015 Feb; 26(1):49-53. PubMed ID: 24552591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.
    Fonseca E; Iglesias R; Paradela S; Fernández-Torres RM; Elberdín L
    J Dermatolog Treat; 2015 Jun; 26(3):217-22. PubMed ID: 24920071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre.
    Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1298-303. PubMed ID: 21967627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
    Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
    Tan E; Baker C; Foley P
    Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.